An Insight into the Genetic Study and Pathogenesis of the Colorectal Cancer

Dr. Tapan Behl

Authors

Dr. Tapan Behl

Keywords:

adenomatous polyp, APC gene, LOH group, MSI-positive group, beta-catenin

Abstract

Colorectal cancer is defined as the cancer of the large intestine or the rectum -thus attributing to some other names related to this cancer such as -bowel cancer or rectal cancer, depending on the site where the tumor has occurred. It mostly begins as a benign tumor with then turns into a carcinoma.Colon cancer and rectal cancer are related in terms of their genetics and thus are studied together as allied tumors. Although some other factors such as age and lifestyle are also concerned with the progression of this cancer, a minority group of people acquire it because of certain genetic predisposition, which is focused upon in this review. Initially it was thought only to occur because of certain mutations in a specific gene called adenomatous polyposis coli (APC) gene which are responsible for initiating the characteristic events which lead to the progression of this tumor.The cases affected by this pathway were called the LOH group. But further researches concluded that there is another different pathway which can lead to the occurrence of this tumor apart from the one briefly stated above.

Downloads

How to Cite

An Insight into the Genetic Study and Pathogenesis of the Colorectal Cancer. (2014). Global Journal of Medical Research, 14(28), 29-36. https://medicalresearchjournal.org/index.php/GJMR/article/view/

Download Citation

References

S. Landis, T. Murray, S. Bolden (1999) Cancer statistics. 49(1), 8-31. https://doi.org/10.3322/canjclin.49.1.8

F. Berrino, R. De Angelis, M. Sant (2007) et al.Survival for eight major cancers and all cancers combined for European adults diagnosed in 1995-99: results of the EUROCARE-4 study. 8, 773-783.

Rebecca Siegel, Jiemin Ma, Zhaohui Zou, Ahmedin Jemal (2014) Cancer statistics. 64(1), 9-29. https://doi.org/10.3322/caac.21208

N. Becker (2003) Epidemiology of colorectal cancer. Der. 43(2), 98-104.

F. Jemal (2011) Global cancer statistics. 61(2), 69-90.

S. Majumdar, R. Fletcher, A. Evans (1999) How Does Colorectal Cancer Present? Symptoms, Duration, and Clues to Location. 94(10), 3039-3045.

R. Fletcher (2009) The diagnosis of colorectal cancer in patients with symptoms: finding a needle in a haystack. 17, 18.

K. Bielecki, P. Kaminski, M. Klukowski (2002) Large bowel perforation: morbidity and mortality. 6(3), 177-182. https://doi.org/10.1007/s101510200039

L. Bianchi, C. Burke Understanding current guidelines for colorectal cancer screening: a casebased approach. Cleve. Clin. J. 75(6), 441-448.

D. Alexander, C. Cushing (2011) Red meat and colorectal cancer: a critical summary of prospective epidemiologic studies. 12(5), 472-493. https://doi.org/10.1111/j.1467-789x.2010.00785.x

M. Boutron, M. Wilpart, J. Faivre (1991) Diet and colorectal cancer. 1(Suppl 2), 13-20. https://doi.org/10.1097/00008469-199110002-00003

E. Giovannucci (2001) An Updated Review of the Epidemiological Evidence that Cigarette Smoking Increases Risk of Colorectal Cancer. Cancer Epidemiol. 10(7), 725-731.

N. Homann, J. Tillonen, M. Salaspuro (2000) Microbially produced acetaldehyde from ethanol may increase the risk of colon cancer via folate deficiency. Int. J. 86(2), 169-173.

A. Wu, A. Paganini-Hill, R. Ross, B. Henderson (1987) Alcohol, physical activity and other risk factors for colorectal cancer: A prospective study. 55(6), 687-694.

Elizabeth Half, Dani Bercovich, Paul Rozen (2009) Familial adenomatous polyposis. 4(1), 22. https://doi.org/10.1186/1750-1172-4-22

S. Dolwani, S. Jones, D. Eccles (2003) et al. Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH. 362(9377), 39-41.

Robert Gryfe (2009) Inherited Colorectal Cancer Syndromes. 22(04), 198-208. https://doi.org/10.1055/s-0029-1242459

F. Piard, L. Martin, C. Chapusot, T. Ponnelle, J. Faivre (2002) Genetic pathways in colorectal cancer: interest for the pathologist. Ann. 1(4), 277-288.

P. Morin, A. Sparks, V. Korinek (1997) Activation of β-Catenin-Tcf Signaling in Colon Cancer by Mutations in β-Catenin or APC. 275(5307), 1787-1790. https://doi.org/10.1126/science.275.5307.1787

L. Jin, Q. Shao, W. Luo (2003) et al. Detection of point mutations of the Axin1 gene in colorectal cancers. Int. J. 107(5), 696-699.

W. Liu (2000) Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating β-catenin/TCF signalling. 26(2), 146-147.

P. Hatzis, L. van der Flier, M. van Driel (2008) et al. Genome-Wide Pattern of TCF7L2/TCF4 Chromatin Occupancy in Colorectal Cancer Cells. Mol. 28(8), 2732-2744.

J. Guo, T. Cagatay, G. Zhou (2009) Mutations in the Human naked cuticle Homolog NKD1 Found in Colorectal Cancer Alter Wnt/Dvl/β-Catenin Signaling. 4(11), e7982. https://doi.org/10.1371/journal.pone.0007982

S. Libutti, L. Saltz, J. Tepper (2008) Colon cancer. 1, 1232-84.

C. Compton, E. Hawk, L. Grochow, F. Lee, M. Ritter, J.E.Niederhuber (2008) 2008, 1477-534.

S. Markowitz, D. Dawson, J. Willis, J. Willson (2002) Focus on colon cancer. 1(3), 233-236.

T. Andre, C. Boni, L. Mounedji-Boudiaf (2004) et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N. Engl. J. 350(23), 2343-2351.

V. Korinek, N. Barker, P. Morin (1997) Constitutive Transcriptional Activation by a β-Catenin-Tcf Complex in APC −/− Colon Carcinoma. 275(5307), 1784-1787.

K. Goss, J. Groden (2000) Biology of the adenomatous polyposis coli tumor suppressor. 18(9), 1967-79.

M. Prieve, M. Waterman (1999) Nuclear Localization and Formation of β-Catenin-Lymphoid Enhancer Factor 1 Complexes Are Not Sufficient for Activation of Gene Expression. 19, 4503-4515.

K. Kinzler, B. Vogelstein (2002) Colorectal tumors. 2002, 583-612.

Arnold Levine (1997) p53, the Cellular Gatekeeper for Growth and Division. 88(3), 323-331. https://doi.org/10.1016/s0092-8674(00)81871-1

S. Baker, E. Fearon, J. Nigro (1989) et al. Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. 244, 217-221.

S. Baker, A. Preisinger, J. Jessup (1990) et al. p53 Gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. 50, 7717-7722.

G. Riggins, S. Thiagalingam, E. Rozenblum (1996) et al. MAD-related genes in the human. Nat. 13, 347-349.

Jing Fang, Bruce Richardson (2005) The MAPK signalling pathways and colorectal cancer. 6(5), 322-327. https://doi.org/10.1016/s1470-2045(05)70168-6

J. Bos, E. Fearon, S. Hamilton (1987) et al. Prevalence of RAS gene mutations in human colorectal cancers. 327(6120), 293-297.

M. O (2007) Hyperplastic and serrated polyps of the colorectum. 36(4), 947-68.

H. Davies, G. Bignell, C. Cox (2002) et al. Mutations of the BRAF gene in human cancer. 417(6892), 949-954.

Y. Samuels, Z. Wang, A. Bardelli (2004) et al. High frequency of mutations of the PIK3CA gene in human cancers. 304(5670), 554-554. https://doi.org/10.1126/science.1096502

D. Parsons, T. Wang, Y. Samuels (2005) et al. Colorectal cancer: mutations in a signalling pathway. 436(7052), 792-792. https://doi.org/10.1038/436792a

S. Jones, W. Chen, G. G (2008) Comparative lesion sequencing provides insights into tumor evolution. 105, 4283-8.

M. Yan, R. Rerko, P. Platzer (2004) Hydroxyprostaglandin dehydrogenase, a COX-2 oncogene antagonist, is a TGF-beta-induced suppressor of human gastrointestinal cancers. 101(50), 7468-73.

G. Steinbach, P. Lynch, R. Phillips (2000) et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. 342.

L. Saltz, N. Meropol, P. Loehrer, M. Needle, J. Kopit, R. Mayer (2004) Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J.Clin. 22(7), 1201-1208.

M. Jhawer, S. Goel, A. Wilson (2008) et al. PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. 68(6).

H. Hurwitz, L. Fehrenbacher, W. Novotny (2004) et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. 350(23), 2335-2342.